Substipharm acquires IMOJEV®

SUBSTIPHARM is proud to announce that it entered into an agreement to acquire the Japanese Encephalitis vaccine IMOJEV® from Sanofi for an undisclosed amount.

IMOJEV® is indicated for the prevention of Japanese Encephalitis in both adults and children, and is currently marketed in Australia, Brunei, Cambodia, Hong Kong, Indonesia, Malaysia, Myanmar, Philippines, Taiwan, Thailand Singapore, South Korea, Sri Lanka, Vietnam.

As a French based privately-owned company, SUBSTIPHARM will not only dedicate all efforts in consolidating IMOJEV®’s market share in its current territories but will also heavily invest to extend this vaccine availability globally.

Leopold Berthier, Substipharm Chief Executive Officer, commented:

“This acquisition provides a massive breakthrough for Substipharm entering a new therapeutic area and reaching new geographies across Asia Pacific. Prevention is a strategic focus for our company, and we aspire to be a recognized partner for vaccines in the long term. This vaccine protects people and saves lives against a disease for which there is currently no curative treatment. With IMOJEV®, Substipharm is taking another step forward to support its rapid growth pattern outside Europe”.

Thomas Grenier, Head of Sanofi Vaccines Franchise & Product Strategy, commented:

“We are pleased to have reached an agreement with Substipharm, a trusted pharmaceutical company committed to realize the full potential of this vaccine internationally. This sale supports our strategic ambition to focus our resources on transforming the practice of medicine with new innovative medicine and vaccines while also ensuring the continued availability of the life-saving vaccine for populations in need”.

The closing of the transaction, subject to customary closing conditions, including certain approvals, is expected in September 2022.